

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
09 March 2023 (09.03.2023)



(10) International Publication Number
WO 2023/034923 A2

(51) International Patent Classification:
C07K 16/30 (2006.01) A61K 39/395 (2006.01)

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:
PCT/US2022/075847

Published:

- without international search report and to be republished
upon receipt of that report (Rule 48.2(g))
- with sequence listing part of description (Rule 5.2(a))

(22) International Filing Date:
01 September 2022 (01.09.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/240,404 03 September 2021 (03.09.2021) US

(71) Applicant: NOVAROCK BIOTHERAPEUTICS, LTD.
[US/US]; 801 Charles Ewing Blvd., Ewing, New Jersey
08628 (US).

(72) Inventors: PEI, Yi; 1836 Glenwold Drive, Paoli, New
Jersey 19301 (US). HUANG, Haichun; 4329 Crestwood
Street, Fremont, California 94538 (US). LOI, Yick; 23
Windsor Drive, East Brunswick, New Jersey 08816 (US).
CHEN, Chang Hung; 13623 Palmetto Circle, German-
town, Maryland 20874 (US). LI, Han; 1 Claire Dr., New-
town, Pennsylvania 18940 (US). SHEN, Di; 119 Bedford
Ct, Piscataway, New Jersey 08854 (US). LEI, Ming; 20
Lockwood Drive, Princeton, New Jersey 08540 (US).

(74) Agent: MORGAN, LEWIS & BOCKIUS LLP; 110
North Wacker Drive, Suite 2800, Chicago, Illinois 60606
(US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: BISPECIFIC AND TRISPECIFIC BINDING PROTEINS TO PD-L1, CD137, AND/OR TGF-BETA AND USES THERE-
OF

(57) Abstract: The disclosure provides binding proteins that bind PD-L1 and CD137 (PD-L1/CD137 bispecific), binding proteins
that bind PD-L1 and TGFβ (PD-L1/TGFβ bispecific), binding proteins that bind PD-L1, TGFβ, and CD137 (PD-L1/TGFβ/CD137
trispecific), and binding proteins that bind CD137, TGFβ, and PD-L1 (CD137/TGFβ/PD-L1 trispecific). The disclosure also provides
pharmaceutical compositions comprising these binding proteins, and methods of their use to treat and/or prevent cancer.

WO 2023/034923 A2